Clinical trials: Over Eating
Malnutrition
Study to Assess Safety and Efficacy of Kabiven® in Pediatric Patients 2 to 16 Years of Age
Demonstrate the safety and efficacy of Kabiven compared to standard parenteral nutrition (PN) administered via central vein in pediatric patients (2 to 16 years of age) requiring PN to meet nutritional needs.
- Trial name
- NCT03481894
- Testing
- Kabiven®, Compounded standard parenteral nutrition
- Where
- 2 sites in United States
- Sponsor
- Fresenius Kabi
Diabetes Mellitus, Type 2, Obesity
Investigation Of Weight Loss And Body Composition Changes After Dosing With Either Placebo Or One Of Two Active Drugs
The drugs GSK189075 and GW869682 result in increased caloric losses. This study is investigating how if taken over 8 weeks that affects weight loss, food intake and the composition of the body.
- Trial name
- NCT00494767
- Testing
- GW869682, GSK189075
- Where
- United Kingdom
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Prader-Willi Syndrome
Study to Evaluate Efficacy, Safety, and Tolerability of RGH-706 in Prader-Willi Syndrome
RGH-706 is a novel, potent, and orally active MCHR1 antagonist drug candidate discovered and being developed by Gedeon Richter Plc. for weight management.
- Trial name
- NCT05322096
- Testing
- RGH-706
- Where
- 23 sites in United States, Czechia and 3 more
- Volunteers
- 39 people
- Sponsor
- Gedeon Richter Plc.
Critical Illness
Observational Cohort Study on the Use of Parenteral Nutrition and Clinical Outcomes in Adult Critically Ill Patients
The aim of this study is to characterise the use of clinical nutrition support, especially of parenteral nutrition that is administered directly into a vein, in adult patients with critical illness.
- Trial name
- NCT04143503
- Where
- 76 sites in Austria, Belgium and 9 more
- Volunteers
- 1,208 people
- Sponsor
- Fresenius Kabi
Parenteral Nutrition (No Primary Condition Studied)
Dosing Study of Amino Acids in Seriously Ill Patients
The purpose of this study is to determine the best rate of infusion of amino acids (15% CLINISOL - sulfite-free (Amino Acid) Injection) for nutrition in subjects with with stages II to IVB head and neck cancer.
- Trial name
- NCT01923480
- Testing
- 15% CLINISOL - Sulfite-free (Amino Acid) Injection
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- Baxter Healthcare Corporation
Binge Eating, Obesity
Feasibility of a Digital Therapeutic for Adults With Binge Eating and Obesity
The primary objective of this study is to test the feasibility of a digital therapeutic to address comorbid binge eating and obesity in adults.
- Trial name
- NCT06454123
- Testing
- OTX-401
- Volunteers
- 30 people
- Sponsor
- Oui Therapeutics, Inc.
Prader-Willi Syndrome, Obesity
A Study of Setmelanotide in Patients With Prader-Willi Syndrome
This is a Phase 2, open-label study designed to assess the safety and efficacy of setmelanotide in patients with obesity due to Prader-Willi Syndrome (PWS) who are 6 to 65 years of age.
- Conditions
- Prader-Willi Syndrome, Obesity, Hyperphagia
- Trial name
- NCT06772597
- Testing
- Setmelanotide
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Rhythm Pharmaceuticals, Inc.
Short Bowel Syndrome
Safety and Efficacy Study of Teduglutide in Subjects With Short Bowel Syndrome Who Completed Protocol CL0600-004 (NCT00081458)
The purpose of this clinical study is to evaluate the long-term safety and efficacy of daily administration of teduglutide.
- Trial name
- NCT00172185
- Testing
- teduglutide 0.05 mg/kg/d, teduglutide 0.10 mg/kg/d
- Where
- 21 sites in United States, Belgium and 6 more
- Volunteers
- 65 people
- Sponsor
- Shire
Healthy, Overweight
Study to Evaluate the Effect of Gum Acacia (FibregumTM) on Post-prandial Glucose, Insulin Levels and Food Intake
Study to evaluate the effect of gum acacia (FibregumTM) on post-prandial glucose and insulin levels and food intake in normal-weight and overweight subjects during a 2-7 weeks intervention period.
- Trial name
- NCT04515277
- Testing
- 40 g Gum acacia (FibregumTM), 20 g Gum acacia (FibregumTM), 0 g Gum acacia (FibregumTM)
- Where
- Germany
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Nexira
Obesity, Genetic Obesity
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway
The protocol describes a randomized, double-blind, placebo-controlled trial with independent sub-studies of setmelanotide in patients with obesity and at least one of the specific gene variants in the Melanocortin-4 Receptor…
- Trial name
- NCT05093634
- Testing
- Setmelanotide
- Where
- 56 sites in United States, Canada and 8 more
- Volunteers
- 296 people
- Sponsor
- Rhythm Pharmaceuticals, Inc.
Critical Illness
ICULIP, Influence of Two Lipid Emulsions in the Nosocomial Infection in Critical Patients
This study aims to analyse the effect of two total parenteral nutrition diets with lipid emulsions of different compositions on the incidence of nosocomial infection in critical patients.
- Trial name
- ICULIP (NCT00396461)
- Testing
- MCT/LCT (1:1), MCT/LCT/omega-3 (5:4:1)
- Where
- 22 sites in Spain
- Volunteers
- 212 people
- Sponsor
- B. Braun Medical SA
Nutrition Support
Comparative Phase 3 Trial to Assess the Safety and Efficacy of Triple-chamber Parenteral Nutrition Formulation
The objective of this study is to assess the safety and efficacy of Oliclinomel N4 compared to compounded ternary parenteral nutrition (PN) admixtures for the delivery of PN in hospitalized adults for whom oral or enteral…
- Trial name
- NCT01579097
- Testing
- Oliclinomel N4, Compounded ternary parenteral nutrition admixtures
- Where
- China
- Volunteers
- 458 people
- Sponsor
- Baxter Healthcare Corporation
Bardet-Biedl Syndrome, POMC Deficiency
Phase 3 Crossover Trial of Two Formulations of Setmelanotide in Participants With Specific Gene Defects in the MC4R Pathway
A trial to compare the weekly and daily formulations of setmelanotide in participants with genetic defects in the melanocortin-4 receptor pathway.
- Trial name
- NCT05194124
- Testing
- Setmelanotide 2 mg, Setmelanotide 2.5 mg, Setmelanotide 3 mg
- Where
- 7 sites in United States, Canada and 4 more
- Volunteers
- 19 people
- Sponsor
- Rhythm Pharmaceuticals, Inc.
Short Bowel Syndrome
Open-Label Study of Teduglutide for Subjects With PN-Dependent Short Bowel Syndrome (SBS)
This study is a 2-year open label extension study to collect long term efficacy and safety data from patients who have completed the 24-weeks of study drug dosing in CL0600-020.
- Trial name
- NCT00930644
- Testing
- teduglutide
- Where
- 23 sites in United States, Canada and 7 more
- Volunteers
- 88 people
- Sponsor
- Shire
HIV Infections
A Comparison of Two Types of Injected Nutritional Supplements in Patients With AIDS and Pneumocystis Carinii Pneumonia (PCP)
The objectives of this study are: To establish whether there is a difference in clinical effectiveness of Liposyn II 20 percent as compared with Liposyn III 2 percent in AIDS patients with Pneumocystis carinii pneumonia (PCP).
- Trial name
- NCT00002275
- Testing
- Fat Emulsion 2%, Fat Emulsion 20%
- Where
- United States
- Sponsor
- Abbott
Pediatric Intestinal Failure
KiteLock 4% EDTA Lock Solution for the Prevention of Occlusions in Children With Intestinal Failure
A multi-site, randomized, 2-arm open-label trial to determine if 4% Tetrasodium (EDTA) catheter lock solution is more effective than heparin lock (standard of care) in preventing central venous catheter occlusions in children…
- Trial name
- NCT05879835
- Testing
- KiteLock 4% Sterile Catheter Lock Solution, Heparin Lock Solution
- Where
- 8 sites in United States
- Volunteers
- 124 people
- Sponsor
- SterileCare Inc.
Parenteral Nutrition
Clinical Trial to Evaluate the Safety and Efficacy of IN-C006 Peri Inj. Compared With RPN301
This study is designed to evaluate the safety and efficacy of IN-C006 Peri inj. and RPN301 in postoperative patients requiring central parenteral nutrition.
- Trial name
- NCT05337228
- Testing
- IN-C006 Peri inj., RPN301
- Where
- South Korea
- Volunteers
- 59 people
- Sponsor
- HK inno.N Corporation
Malnutrition, Infant, Enteral Feeding Intolerance
Efficacy and Safety of Numeta G13%E Compared to Compounded Parenteral Nutrition in Preterm Neonates
Preterm (PT, born before 37 weeks of gestation) birth complications are the leading causes of death among children aged under 5 years globally, with nearly one million infant deaths reported in 2013.
- Trial name
- NCT06894446
- Testing
- Numeta G13%E, Compounded Parenteral Nutrition (cPN) solution
- Volunteers
- healthy volunteers welcome
- Sponsor
- Baxter Healthcare Corporation
Veinous, Chemotherapy
A Retrospective, Observational, Multicenter Study to Evaluate the Safety and Performance of POLYSITE® and SEESITE® Implantable Ports
The purpose of this study is to evaluate performance and safety of POLYSITE® and SEESITE® implantable ports allowing repeated and prolonged access to the venous system for the administration of chemotherapy, antibiotics…
- Conditions
- Veinous, Chemotherapy, Antibiotics, Antiviral Drugs
- Trial name
- NCT05519761
- Testing
- Implantation of veinous access ports
- Where
- 3 sites in France
- Volunteers
- 250 people
- Sponsor
- Perouse Medical
Intestinal Failure
AI-driven Total Parenteral Nutrition Platform
This study tests whether an artificial intelligence (AI) tool can help doctors order total parenteral nutrition (TPN) for babies in the neonatal intensive care unit (NICU).
- Trial name
- NCT07414576
- Testing
- AI-driven total parenteral nutrition (TPN)
- Where
- United States
- Volunteers
- 260 people
- Sponsor
- Takeoff41, Inc.